Compare Repligen Corporation Common Stock (RGEN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs DENTSPLY SIRONA Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while DENTSPLY SIRONA Inc trades at $8.54 (market cap $1.68B). The key difference: Repligen Corporation Common Stock is far larger — about 6.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| RGEN | XRAY | |
|---|---|---|
Market Cap | $11.31B | $1.68B |
Volume | 1,216,919 | 3,968,929 |
Sector | Health | Health |
52-Week High | $194.57 | $14.68 |
52-Week Low | $102.87 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $11.20B | $3.76B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
DENTSPLY SIRONA (XRAY) trades at $8.505, down 0.29% and near 52-week lows, with bearish technical signals and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating estimates but faces declining revenue and negative margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid weak dental market conditions.
The stock presents a high-risk opportunity with analyst consensus at $12.50 (47% upside) but requires careful monitoring of margin recovery and sales stabilization. Key risks include persistent net losses, competitive pressures, and execution challenges in the turnaround plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
